Advertisement
Canada markets open in 46 minutes
  • S&P/TSX

    22,269.12
    +197.42 (+0.89%)
     
  • S&P 500

    5,277.51
    +42.03 (+0.80%)
     
  • DOW

    38,686.32
    +574.82 (+1.51%)
     
  • CAD/USD

    0.7341
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    76.95
    -0.04 (-0.05%)
     
  • Bitcoin CAD

    94,946.28
    +2,237.27 (+2.41%)
     
  • CMC Crypto 200

    1,494.16
    +26.22 (+1.79%)
     
  • GOLD FUTURES

    2,352.70
    +6.90 (+0.29%)
     
  • RUSSELL 2000

    2,070.13
    +13.53 (+0.66%)
     
  • 10-Yr Bond

    4.4690
    -0.0450 (-1.00%)
     
  • NASDAQ futures

    18,685.75
    +94.75 (+0.51%)
     
  • VOLATILITY

    13.12
    +0.20 (+1.55%)
     
  • FTSE

    8,295.89
    +20.51 (+0.25%)
     
  • NIKKEI 225

    38,923.03
    +435.13 (+1.13%)
     
  • CAD/EUR

    0.6765
    +0.0003 (+0.04%)
     

Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Bicycle Therapeutics PLC Sponsored ADR (BCYC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.

Bicycle Therapeutics PLC Sponsored ADR is a member of the Medical sector. This group includes 1047 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Bicycle Therapeutics PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for BCYC's full-year earnings has moved 20.7% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

ADVERTISEMENT

According to our latest data, BCYC has moved about 20.1% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 5% on a year-to-date basis. This means that Bicycle Therapeutics PLC Sponsored ADR is performing better than its sector in terms of year-to-date returns.

Another stock in the Medical sector, Ocugen (OCGN), has outperformed the sector so far this year. The stock's year-to-date return is 233.9%.

Over the past three months, Ocugen's consensus EPS estimate for the current year has increased 9.2%. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, Bicycle Therapeutics PLC Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 506 individual companies and currently sits at #88 in the Zacks Industry Rank. On average, stocks in this group have lost 2.7% this year, meaning that BCYC is performing better in terms of year-to-date returns. Ocugen is also part of the same industry.

Investors interested in the Medical sector may want to keep a close eye on Bicycle Therapeutics PLC Sponsored ADR and Ocugen as they attempt to continue their solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bicycle Therapeutics PLC Sponsored ADR (BCYC) : Free Stock Analysis Report

Ocugen, Inc. (OCGN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research